Xenon Pharmaceuticals Inc. reported $0 of revenue over the trailing twelve months, −100% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q2 2026). Net income: −$409M, trailing twelve months to Q2 2026. Free cash flow: −$339M, trailing twelve months to Q2 2026. EPS: −$4.74, trailing twelve months to Q2 2026.

XENEXenon Pharmaceuticals Inc.

Healthcare

$36.44-1.4% 1Y

$36.44

$36.1752 weeks$68.91

XENE as reported

Xenon Pharmaceuticals Inc. reported $0 of revenue over the trailing twelve months, −100% on the year before. 9 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q2 2026 · −100% against the twelve months before

Net income: −$409M
Net income · +47% year on year · trailing twelve months to Q2 2026
Free cash flow: −$339M
Free cash flow · +46% year on year · trailing twelve months to Q2 2026
EPS: −$4.74
EPS · +34% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for XENE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	−100%	Q2 2026
Net income	−$409M	+47%	Q2 2026
EPS	−$4.74	+34%	Q2 2026
Operating margin	−8851%	n/a	Q3 2022 · 15 quarters behind
Net margin	−8716%	n/a	Q3 2022 · 15 quarters behind
ROE	−44%	n/a	Q2 2026
ROA	−41%	n/a	Q2 2026
ROIC	460%	n/a	Q1 2020 · 25 quarters behind
Free cash flow	−$339M	+46%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.